Recombinant Biotinylated Human OX40/TNFRSF4/CD134 Protein (Primary Amine Labeling),hFc Tag性能參數(shù)分子別名（Synonyms）OX40Lreceptor;CD134;TNFRSF4;Ly-70表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）BiotinylatedHumanOX40/TNFRSF4/CD134Protein(PrimaryAmineLabeling)isexpressedfromHEK293withhFctagattheC-Terminus.ItcontainsLeu29-Ala216.[Accession|P43489]分子量大?。∕olecularWeight）TheproteinhasapredictedMWof46.8kDa.Duetoglycosylation,theproteinmigratesto72-75kDabasedonSDS-PAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedbySDS-PAGE制劑（Formulation）Suppliedas0.22μmfilteredsolutioninPBS(pH7.4).儲存條件Theproductshouldbestoredat-85~-65℃for1yearfromdateofreceipt.Recommendtoaliquottheproteinintosmallerquantitieswhenfirstusedandavoidrepeatedfreeze-thawcycles.（CDNF），也稱為甲型蛋白1，是由CDNF基因編碼的蛋白質(zhì)，它在神經(jīng)元和非神經(jīng)元組織中有表達(dá)。Recombinant Human LILRA4/CD85g(His-Avi Tag)

ERBB3,又稱HH3(人表皮生長因子受體3),是一種I型膜糖蛋白,是酪氨酸激酶受體ERBC家族的成員。ERBP家族成員作為表皮生長因子(LU)家族的生長因子的受體。在ERBP家庭成員中,因?yàn)樗幸粋€缺陷的激酶域。ERBB3在角化細(xì)胞、黑色素細(xì)胞、骨骼肌細(xì)胞、成肌細(xì)胞和雪旺細(xì)胞中都有表達(dá)。單體ERbb3是一種低親和性的受體。ERBB3與ERBB2的異聚反應(yīng)形成高親和性受體復(fù)合物。與此相反,ERBB3同向聚合或異向聚合形成了一個低親和性的結(jié)合物。因?yàn)镋RBB3含有一個有缺陷的激酶域,ERBB2的激酶域負(fù)責(zé)通過異二重瓣受體啟動酪氨酸磷酸化信號。研究發(fā)現(xiàn),ERBB3細(xì)胞質(zhì)區(qū)內(nèi)的三個離散氨基酸信號對ERBB2的轉(zhuǎn)導(dǎo)至關(guān)重要。ERBB3的細(xì)胞質(zhì)域也包含6個一致的結(jié)合主題,用于調(diào)節(jié)P85磷酸酶3激酶(PI3K)的HS2領(lǐng)域,以及一個豐富的一致的結(jié)合主題。ERBB3的細(xì)胞質(zhì)域也包含6個一致的結(jié)合主題,用于調(diào)節(jié)P85磷酸酶3激酶(PI3K)的HS2領(lǐng)域,以及一個豐富的一致的結(jié)合主題。ERBB3的細(xì)胞質(zhì)域也包含6個一致的結(jié)合主題,用于調(diào)節(jié)P85磷酸酶3激酶(PI3K)的HS2領(lǐng)域,以及一個豐富的一致的結(jié)合主題。表達(dá)區(qū)間及表達(dá)系統(tǒng)重組的人HR3/ERBB3蛋白表達(dá)自于C-端的HK293細(xì)胞和AVI標(biāo)記。里面有血清20-Thr643。分子量大約71.6Recombinant Human Ubiquitin Activating Enzyme E1 (UBE1)重組腸激酶（rEK）是一種高純度的重組牛腸激酶輕鏈片段，氨基酸序列與牛腸激酶輕鏈一致，有著酶切位點(diǎn)。

3C蛋白酶是切割小RNA病毒科非結(jié)構(gòu)蛋白的關(guān)鍵酶，在病毒復(fù)制過程中發(fā)揮著重要作用。鼻病毒屬于小RNA病毒科，其中的人鼻病毒3C蛋白酶基因編碼區(qū)全長552bp，編碼的蛋白質(zhì)相對分子質(zhì)量約為22000Da。人鼻病毒3C蛋白酶具有高度的酶切特異性，能特異切割位于Gln-Gly之間的肽鍵，識別位點(diǎn)為Leu-Glu-Val-Leu-Phe-Gln↓Gly-Pro。本公司將人鼻病毒3C蛋白酶的編碼區(qū)基因，在大腸桿菌中進(jìn)行重組表達(dá)，純化后獲得了高純度的重組3C蛋白酶，該蛋白酶能特異切割含有3C酶切位點(diǎn)的融合蛋白，具有良好的生物學(xué)活性。同時，本公司生產(chǎn)的3C蛋白酶帶有GST和MAT標(biāo)簽蛋白，有利于后期將其從酶切體系中去除。產(chǎn)品性質(zhì):中文別名（Chinesesynonym）:3C蛋白酶英文別名（Englishsynonym）:3CProtease來源（Source）:大腸桿菌表達(dá)標(biāo)簽（label）:GST-3CProtease-MAT純度（Purity）:經(jīng)SDS-PAGE及HPLC分析，純度>95%分子量（Molecularweight）:47.38kDa比活性（Specificactivity）:500U/ml緩沖液組分（Buffer）:50mMTris-HCl，150mMNaCl，1mMEDTA，1mMDTT，pH7.0酶活定義（UnitDefinition）:在緩沖液中切割100μg被檢測的融合蛋白，反應(yīng)條件為4℃16小時,切割率≥90%運(yùn)輸和保存方法:干冰運(yùn)輸；保存于-20℃。

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.通過泛素-蛋白體途徑(UPP)中的酶與底物蛋白共價連接，并在26S蛋白體降解ATP依賴的細(xì)胞蛋白中發(fā)揮主要作用。

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS?CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 .The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). Before binding to the ACE-2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy. Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE-2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy.  FGF-18與FGF R2C，F(xiàn)GF R3C以及高爾基蛋白GLG1結(jié)合，并誘導(dǎo)星形膠質(zhì)細(xì)胞和小膠質(zhì)細(xì)胞。Recombinant Human KGF/FGF-7 Protein

雙堿性內(nèi)切酶又稱為Kex2蛋白酶、YSCF蛋白酶，在酵母體內(nèi)Kex2蛋白酶負(fù)責(zé)加工killer toxin和α-factor的前體。Recombinant Human LILRA4/CD85g(His-Avi Tag)

性能參數(shù)表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）CynomolgusCD27Ligand/CD70ProteinisexpressedfromHEK293withHistagattheN-terminal.ItcontainsGln39-Pro194.[Accession|G7PYU6-1]分子量大小（MolecularWeight）TheproteinhasapredictedMWof18.4kDa.Duetoglycosylation,theproteinmigratesto60-90kDabasedonTris-BisPAGEresult.（Endotoxin）Lessthan1EUperugbytheLALmethod.純度（Purity）>95%asdeterminedbyTris-BisPAGE活性（Activity）ELISAData:ImmobilizedCynomolgusCD27Ligand,HisTagat2μg/ml(100μl/well)ontheplate.DoseresponsecurveforCynomolgus/RhesusmacaqueCD27,hFcTagwiththeEC50of70.8ng/mldeterminedbyELISA.制劑（Formulation）Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法（Reconstitution）Centrifugetubesbeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.Recombinant Human LILRA4/CD85g(His-Avi Tag)

浦斯瑞（上海）生物醫(yī)藥有限公司匯集了大量的優(yōu)秀人才，集企業(yè)奇思，創(chuàng)經(jīng)濟(jì)奇跡，一群有夢想有朝氣的團(tuán)隊(duì)不斷在前進(jìn)的道路上開創(chuàng)新天地，繪畫新藍(lán)圖，在江蘇省等地區(qū)的化工中始終保持良好的信譽(yù)，信奉著“爭取每一個客戶不容易，失去每一個用戶很簡單”的理念，市場是企業(yè)的方向，質(zhì)量是企業(yè)的生命，在公司有效方針的領(lǐng)導(dǎo)下，全體上下，團(tuán)結(jié)一致，共同進(jìn)退，**協(xié)力把各方面工作做得更好，努力開創(chuàng)工作的新局面，公司的新高度，未來浦斯瑞（上海）生物醫(yī)藥供應(yīng)和您一起奔向更美好的未來，即使現(xiàn)在有一點(diǎn)小小的成績，也不足以驕傲，過去的種種都已成為昨日我們只有總結(jié)經(jīng)驗(yàn)，才能繼續(xù)上路，讓我們一起點(diǎn)燃新的希望，放飛新的夢想！